Stock BIO.B BIO-RAD LABORATORIES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Bio-Rad Laboratories, Inc. Nyse

Equities

BIO.B

US0905721082

Medical Equipment, Supplies & Distribution

Market Closed - Nyse
Other stock markets
 04:15:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
279.9 USD 0.00% Intraday chart for Bio-Rad Laboratories, Inc. 0.00% -12.71%
Apr. 26 Bio-Rad Laboratories, Inc. Announces Executive Vice President and President Changes, Life Science Group CI
Apr. 15 Zacks Investment Research Lowers Price Target on Bio-Rad Laboratories to $285 From $322 MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 11,075 17,345 22,439 12,460 9,399 7,890 - -
Enterprise Value (EV) 1 10,400 17,345 22,439 11,868 8,992 7,229 6,645 6,621
P/E ratio - 4.62 x 5.38 x - -14.8 x 18.1 x 15.8 x 10.5 x
Yield - - - - - - - -
Capitalization / Revenue 4.79 x 6.81 x 7.68 x 4.45 x 3.52 x 2.91 x 2.76 x 2.69 x
EV / Revenue 4.5 x 6.81 x 7.68 x 4.24 x 3.37 x 2.66 x 2.33 x 2.26 x
EV / EBITDA 26.7 x 32.3 x 33.1 x 17.8 x 16.8 x 14.8 x 11.6 x 11.4 x
EV / FCF 28.9 x 36.4 x 41.9 x 127 x 24 x 30.7 x 13.8 x 9.35 x
FCF Yield 3.46% 2.75% 2.39% 0.79% 4.17% 3.26% 7.23% 10.7%
Price to Book - - - 1.27 x 1.05 x 0.87 x 0.84 x 0.8 x
Nbr of stocks (in thousands) 29,935 29,831 29,918 29,824 29,145 28,518 - -
Reference price 2 370.0 582.9 755.6 420.5 322.9 275.9 275.9 275.9
Announcement Date 2/13/20 2/11/21 2/10/22 2/16/23 2/15/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 2,312 2,546 2,923 2,802 2,671 2,713 2,856 2,932
EBITDA 1 389.6 537.4 677.5 667.9 535.9 489.7 573.8 579.4
EBIT 1 278.5 426.6 571.2 524 378.9 361 441 443.6
Operating Margin 12.05% 16.76% 19.54% 18.7% 14.19% 13.31% 15.44% 15.13%
Earnings before Tax (EBT) 1 - 4,908 5,438 - -850.1 570 652.1 1,016
Net income 1 - 3,806 4,246 -3,628 -637.3 444 508.9 790
Net margin - 149.52% 145.28% -129.45% -23.86% 16.37% 17.82% 26.95%
EPS 2 - 126.2 140.6 - -21.82 15.27 17.48 26.16
Free Cash Flow 1 359.4 476.4 535.7 93.7 374.9 235.4 480.5 708
FCF margin 15.55% 18.71% 18.33% 3.34% 14.04% 8.68% 16.83% 24.15%
FCF Conversion (EBITDA) 92.24% 88.64% 79.08% 14.03% 69.97% 48.08% 83.75% 122.19%
FCF Conversion (Net income) - 12.52% 12.62% - - 53.03% 94.43% 89.62%
Dividend per Share 2 - - - - - - - -
Announcement Date 2/13/20 2/11/21 2/10/22 2/16/23 2/15/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 747 732.8 700.1 691.1 680.8 730.3 676.8 681.1 632.1 681.2 626.1 659.6 669.7 736.9 651.4
EBITDA 1 179.3 140 179.5 156.2 132.3 156.5 148.5 137.9 112.7 136.8 91.31 111 127.1 158.9 116.1
EBIT 1 138.5 112.8 153.8 129.9 105.8 127 84.17 107.9 81.59 105.2 61.77 81.44 92.57 124 83.52
Operating Margin 18.54% 15.39% 21.97% 18.79% 15.54% 17.4% 12.44% 15.85% 12.91% 15.45% 9.87% 12.35% 13.82% 16.82% 12.82%
Earnings before Tax (EBT) - - - - - - - -1,500 - - - - - - -
Net income - - - - - 827.7 - -1,162 - 349.7 - - - - -
Net margin - - - - - 113.34% - -170.64% - 51.34% - - - - -
EPS - - - - -5.520 - - -39.59 - - - - - - -
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 10/28/21 2/10/22 4/28/22 7/28/22 10/27/22 2/16/23 5/4/23 8/3/23 10/26/23 2/15/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 675 - - 592 408 661 1,244 1,269
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 359 476 536 93.7 375 235 481 708
ROE (net income / shareholders' equity) - 48.7% 36.1% 3.71% 3.76% 3.32% 3.44% 4.2%
ROA (Net income/ Total Assets) - 36.3% 27.6% - - - - -
Assets 1 - 10,491 15,374 - - - - -
Book Value Per Share 2 - - - 332.0 307.0 316.0 330.0 345.0
Cash Flow per Share - - - 6.530 - - - -
Capex 1 98.5 98.9 121 101 - 171 150 167
Capex / Sales 4.26% 3.89% 4.13% 3.6% - 6.29% 5.27% 5.7%
Announcement Date 2/13/20 2/11/21 2/10/22 2/16/23 2/15/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Bio-Rad Laboratories, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
275.9 USD
Average target price
428.9 USD
Spread / Average Target
+55.43%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

1st Jan change Capi.
ABBOTT LABORATORIES Stock Abbott Laboratories
-2.31% 187B
MEDTRONIC PLC Stock Medtronic plc
-3.20% 106B
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-5.04% 66.9B
DEXCOM, INC. Stock DexCom, Inc.
+0.20% 49.45B
CENCORA, INC. Stock Cencora, Inc.
+17.29% 48B
HOYA CORPORATION Stock Hoya Corporation
+4.06% 40.84B
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+2.07% 26.48B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+2.36% 26.25B
TERUMO CORPORATION Stock Terumo Corporation
+12.96% 24.62B
Other Medical Equipment, Supplies & Distribution
  1. Stock Market
  2. Equities
  3. BIO Stock
  4. BIO.B Stock
  5. Financials Bio-Rad Laboratories, Inc.